Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
Date:11/27/2007

CALGARY, Nov. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia." The claims describe methods of using the reovirus to treat cancers that have inactivated PKR, whether the PKR is inactivated by mutation of Ras or by other factors. PKR is a host cellular protein responsible for preventing virus replication within a cell. Tumour cells lacking the activity of PKR are susceptible to reovirus replication and subsequently, cancer cell killing.

"This patent represents a significant expansion of our intellectual property portfolio," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "The claims cover additional pathways whereby tumours can become susceptible to reovirus infection and cell death."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... Brazil and ... The uptake of several newly approved agents, the ... this indication and the launch of emerging biologics ... markets. In particular, the emerging IL-5 inhibitors will ...
(Date:8/21/2014)... , Aug. 21, 2014  Four-dimensional (4-D) ... behaviors based on external stimuli such as changes ... have a disruptive effect in multiple industries.  In ... business landscape by printing objects ranging from human ... automotive sectors. Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... SoundConnect , a unified ... one of the nation’s Fastest Growing Private Companies ... 2nd consecutive year. Inc. magazine today ranked SoundConnect ... an exclusive ranking of the nation's fastest-growing private ... at the most important segment of the economy—America’s ...
(Date:8/20/2014)... history lessons often have it that American Indians largely ... chicken pox, influenza and tuberculosis brought to the New ... vary, about 20 million people lived in the Americas ... them were killed by European diseases., But new research ... University and Johannes Krause of the University of Tubingen ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... Calif., Nov. 16, 2010 AVANIR Pharmaceuticals, ... it intends to offer and sell shares of its common ... is acting as sole book-running manager in the offering and ... Partners, and Merriman Capital are acting as co-managers for the ...
... ... ... var shortURL ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
... TRIANGLE PARK, N.C., Nov. 16, 2010 Scientists ... data demonstrating that the company,s lipid-conjugated drugs, ... human Organic Anion Transporters (hOATs) and thus have ... mechanism.  These data, presented at the International Pharmaceutical ...
Cached Biology Technology:AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Intel Corporation acquires Toronto start-up CognoVision 2Intel Corporation acquires Toronto start-up CognoVision 3Intel Corporation acquires Toronto start-up CognoVision 4Intel Corporation acquires Toronto start-up CognoVision 5Intel Corporation acquires Toronto start-up CognoVision 6Intel Corporation acquires Toronto start-up CognoVision 7Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 2Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 3Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 4
(Date:8/20/2014)... population-based screening outcomes of approximately 3 million infants, a ... at the University of Massachusetts Medical School, have shown ... be successfully implemented across public health newborn screening programs. ... Aug. 20 issue of the Journal of the ... rate of SCID in newborns is higher than previously ...
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... causes a burning spiciness that is irresistible to some, ... effect are using their findings to develop a new ... be caused by inflammation or other problems. They reported ... in clinical trials, in ACS, Journal of Medicinal ... decades ago, scientists had pegged a compound called capsaicin ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... ,   SPO (SPOM.OB), a leading ... that it has entered into an Investment Agreement,with Dutchess Opportunity ... Under the terms of the signed agreement, for a ... and Dutchess the,obligation to purchase common stock at a 6% ...
... experts from the outside to develop a new energy source ... acknowledge the need to innovate collaboratively if they are to ... NineSigma, the leading provider of Open Innovation and ... organizations is greater than ever, and can make a difference ...
... Lithuania, July 28, 2011 Neurotechnology , ... announced that MegaMatcher and VeriFinger SDK fingerprint compression ... means that the FBI has certified that these ... Scalar Quantization (WSQ) Gray-Scale Fingerprint Image Compression Specification, ...
Cached Biology News:SPO Secures Equity Line Facility of US$5 Million 2SPO Secures Equity Line Facility of US$5 Million 3SPO Secures Equity Line Facility of US$5 Million 4NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 2NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 3NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 4MegaMatcher and VeriFinger SDK Fingerprint Compression Algorithms Receive WSQ Certification from FBI Biometric Center of Excellence 2MegaMatcher and VeriFinger SDK Fingerprint Compression Algorithms Receive WSQ Certification from FBI Biometric Center of Excellence 3
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
CD45/CD34 combination 50 tests...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
Biology Products: